Cytosorbents Corporation provided sales guidance for the second half and full year 2021. The company continue to expect strong growth in core, non-COVID-19 product sales for the remainder of the year, with at least 30% Y-Y growth in the second half of 2021, as well as at least 30% Y-Y growth in full year 2021 core, non-COVID-19 product sales. To be conservative, it expects COVID-19 product sales for the remainder of the year to be less than $1 million. Overall, it expects second half 2021 product sales to exceed first half 2021 product sales.